Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

May 27, 2020

Study Completion Date

May 27, 2020

Conditions
Neuroendocrine TumorsMeningiomaNeuroblastomaMedulloblastoma
Interventions
RADIATION

90Y-DOTA tyr3-Octreotide

90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.

DIAGNOSTIC_TEST

68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan

68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.

DRUG

Amino Acids

This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Iowa

OTHER

NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | Biotech Hunter | Biotech Hunter